CLL1-ADC inhibits colony formation of AML patient samples and tumor growth in the AML PDX model. (A) CLL1-ADC impact on colony formation ability as determined by number of colonies that can be grown from 70 000 PBMCs of AML patient samples. IgG-ADC treatment is shown in green bars, CLL1-ADC in blue bars, and untreated is shown in purple bars. Error bars represent SEM calculated from 3 individually treated wells/plates. (B) AML patient samples (10 × 10⁶ AML patient cells) were injected intravenously into NOD/SCID/IL-2Rγ^−/−. After 6 weeks of tumor cell injection, mice were treated Q1W×3 dosing schedule with CLL1-ADC, and at the end of the ninth week, bone marrow and peripheral blood were collected and analyzed for percentage of human cells. *The group in which datasets are statistically significant (P < .05) relative to control treatment based on 1-way ANOVA analysis.